Which has better valuation & earnings, NVO or ARGX?

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.19 $15.51B $4.26 10.31 argenex $4.25B 13.08 $1.29B $22.46 39.78

Is NVO or ARGX more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% argenex 31.31% 44.37% 37.55%

Does the media favor NVO or ARGX?

In the previous week, Novo Nordisk A/S had 57 more articles in the media than argenex. MarketBeat recorded 64 mentions for Novo Nordisk A/S and 7 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.89 beat argenex's score of 0.77 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 41 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, SNY or ARGX?

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.17 $8.84B $3.58 12.36 argenex $4.25B 13.08 $1.29B $22.46 39.78

Is SNY or ARGX more profitable?

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 44.37% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% argenex 31.31% 44.37% 37.55%

Does the media favor SNY or ARGX?

In the previous week, Sanofi had 1 more articles in the media than argenex. MarketBeat recorded 8 mentions for Sanofi and 7 mentions for argenex. argenex's average media sentiment score of 0.77 beat Sanofi's score of 0.29 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, GSK or ARGX?

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.49 $7.54B $3.85 13.78 argenex $4.25B 13.08 $1.29B $22.46 39.78

Is GSK or ARGX more profitable?

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. argenex's return on equity of 44.37% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% argenex 31.31% 44.37% 37.55%

Does the media prefer GSK or ARGX?

In the previous week, GSK had 25 more articles in the media than argenex. MarketBeat recorded 32 mentions for GSK and 7 mentions for argenex. argenex's average media sentiment score of 0.77 beat GSK's score of 0.17 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 14 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TAK or ARGX?

argenex has a consensus target price of $1,019.50, suggesting a potential upside of 14.10%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 argenex 0 Sell rating(s) 4 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.92

Does the media prefer TAK or ARGX?

In the previous week, argenex had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 7 mentions for argenex and 6 mentions for Takeda Pharmaceutical. argenex's average media sentiment score of 0.77 beat Takeda Pharmaceutical's score of 0.38 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or ARGX?

In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than argenex. MarketBeat recorded 25 mentions for Teva Pharmaceutical Industries and 7 mentions for argenex. Teva Pharmaceutical Industries' average media sentiment score of 1.38 beat argenex's score of 0.77 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 20 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

argenex (ARGX) Competitors

$893.52 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$893.08 -0.43 (-0.05%)

As of 06/12/2026 04:58 PM Eastern

Compare

ARGX vs. NVO, SNY, GSK, TAK, and TEVA

Should you buy argenex stock or one of its competitors? MarketBeat compares argenex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with argenex include Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does argenex compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

In the previous week, Novo Nordisk A/S had 57 more articles in the media than argenex. MarketBeat recorded 64 mentions for Novo Nordisk A/S and 7 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.89 beat argenex's score of 0.77 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	41 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Novo Nordisk A/S currently has a consensus price target of $65.56, indicating a potential upside of 49.34%. argenex has a consensus price target of $1,019.50, indicating a potential upside of 14.10%. Given Novo Nordisk A/S's higher possible upside, research analysts plainly believe Novo Nordisk A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.19	$15.51B	$4.26	10.31
argenex	$4.25B	13.08	$1.29B	$22.46	39.78

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
argenex	31.31%	44.37%	37.55%

Summary

argenex beats Novo Nordisk A/S on 9 of the 17 factors compared between the two stocks.

How does argenex compare to Sanofi?

Sanofi (NASDAQ:SNY) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 44.37% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
argenex	31.31%	44.37%	37.55%

In the previous week, Sanofi had 1 more articles in the media than argenex. MarketBeat recorded 8 mentions for Sanofi and 7 mentions for argenex. argenex's average media sentiment score of 0.77 beat Sanofi's score of 0.29 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.17	$8.84B	$3.58	12.36
argenex	$4.25B	13.08	$1.29B	$22.46	39.78

Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sanofi currently has a consensus target price of $51.00, suggesting a potential upside of 15.25%. argenex has a consensus target price of $1,019.50, suggesting a potential upside of 14.10%. Given Sanofi's higher probable upside, analysts plainly believe Sanofi is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

argenex beats Sanofi on 12 of the 16 factors compared between the two stocks.

How does argenex compare to GSK?

GSK (NYSE:GSK) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. argenex's return on equity of 44.37% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
argenex	31.31%	44.37%	37.55%

In the previous week, GSK had 25 more articles in the media than argenex. MarketBeat recorded 32 mentions for GSK and 7 mentions for argenex. argenex's average media sentiment score of 0.77 beat GSK's score of 0.17 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	14 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.7% of GSK shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.49	$7.54B	$3.85	13.78
argenex	$4.25B	13.08	$1.29B	$22.46	39.78

GSK presently has a consensus price target of $53.00, suggesting a potential downside of 0.08%. argenex has a consensus price target of $1,019.50, suggesting a potential upside of 14.10%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

GSK has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Summary

argenex beats GSK on 13 of the 17 factors compared between the two stocks.

How does argenex compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

argenex has lower revenue, but higher earnings than Takeda Pharmaceutical. argenex is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.79	$1.27B	$0.39	40.81
argenex	$4.25B	13.08	$1.29B	$22.46	39.78

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Takeda Pharmaceutical's net margin of 4.31%. argenex's return on equity of 44.37% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
argenex	31.31%	44.37%	37.55%

In the previous week, argenex had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 7 mentions for argenex and 6 mentions for Takeda Pharmaceutical. argenex's average media sentiment score of 0.77 beat Takeda Pharmaceutical's score of 0.38 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

argenex has a consensus target price of $1,019.50, suggesting a potential upside of 14.10%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

argenex beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.

How does argenex compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

argenex has a net margin of 31.31% compared to Teva Pharmaceutical Industries' net margin of 9.01%. argenex's return on equity of 44.37% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
argenex	31.31%	44.37%	37.55%

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than argenex. MarketBeat recorded 25 mentions for Teva Pharmaceutical Industries and 7 mentions for argenex. Teva Pharmaceutical Industries' average media sentiment score of 1.38 beat argenex's score of 0.77 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	20 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than argenex. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.30	$1.41B	$1.33	26.00
argenex	$4.25B	13.08	$1.29B	$22.46	39.78

Teva Pharmaceutical Industries currently has a consensus target price of $41.78, suggesting a potential upside of 20.83%. argenex has a consensus target price of $1,019.50, suggesting a potential upside of 14.10%. Given Teva Pharmaceutical Industries' higher possible upside, equities research analysts clearly believe Teva Pharmaceutical Industries is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Summary

argenex beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

Get argenex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARGX vs. The Competition

Export

Metric	argenex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.57B	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	39.78	20.00	24.00	24.42
Price / Sales	13.08	306.82	514.36	111.24
Price / Cash	41.88	53.61	27.48	37.92
Price / Book	7.55	8.32	10.54	6.82
Net Income	$1.29B	$23.94M	$3.57B	$337.56M
7 Day Performance	1.26%	1.84%	0.60%	1.17%
1 Month Performance	11.79%	-0.04%	1.56%	3.16%
1 Year Performance	54.62%	44.82%	25.42%	30.58%

argenex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARGX argenex	3.7761 of 5 stars	$893.52 flat	$1,019.50 +14.1%	+54.6%	$55.57B	$4.25B	39.78	1,863
NVO Novo Nordisk A/S	4.2431 of 5 stars	$41.05 -4.4%	$65.56 +59.7%	-45.1%	$191.82B	$46.80B	9.64	69,505	Trending News Analyst Revision
SNY Sanofi	4.0366 of 5 stars	$43.88 -2.5%	$51.00 +16.2%	-10.9%	$109.15B	$49.35B	12.26	74,846
GSK GSK	2.8334 of 5 stars	$50.68 -1.6%	$53.00 +4.6%	+30.0%	$104.54B	$43.07B	13.17	66,841	Dividend Cut
TAK Takeda Pharmaceutical	2.7428 of 5 stars	$15.78 +1.1%	N/A	+4.7%	$49.65B	$28.32B	40.45	47,455

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARGX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenex (ARGX) Competitors

ARGX vs. NVO, SNY, GSK, TAK, and TEVA

How does argenex compare to Novo Nordisk A/S?

Summary

How does argenex compare to Sanofi?

Summary

How does argenex compare to GSK?

Summary

How does argenex compare to Takeda Pharmaceutical?

Summary

How does argenex compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

argenex (ARGX) Competitors

ARGX vs. NVO, SNY, GSK, TAK, and TEVA

How does argenex compare to Novo Nordisk A/S?

Does the media favor NVO or ARGX?

Which has more risk & volatility, NVO or ARGX?

Do analysts recommend NVO or ARGX?

Which has better valuation & earnings, NVO or ARGX?

Do institutionals & insiders believe in NVO or ARGX?

Is NVO or ARGX more profitable?

Summary

How does argenex compare to Sanofi?

Is SNY or ARGX more profitable?

Does the media favor SNY or ARGX?

Which has preferable valuation and earnings, SNY or ARGX?

Which has more volatility & risk, SNY or ARGX?

Do insiders & institutionals hold more shares of SNY or ARGX?

Do analysts rate SNY or ARGX?

Summary

How does argenex compare to GSK?

Is GSK or ARGX more profitable?

Does the media prefer GSK or ARGX?

Do insiders and institutionals have more ownership in GSK or ARGX?

Which has higher earnings & valuation, GSK or ARGX?

Do analysts rate GSK or ARGX?

Which has more volatility and risk, GSK or ARGX?

Summary

How does argenex compare to Takeda Pharmaceutical?

Which has preferable valuation & earnings, TAK or ARGX?

Do institutionals & insiders have more ownership in TAK or ARGX?

Is TAK or ARGX more profitable?

Does the media prefer TAK or ARGX?

Which has more risk & volatility, TAK or ARGX?

Do analysts rate TAK or ARGX?

Summary

How does argenex compare to Teva Pharmaceutical Industries?

Is TEVA or ARGX more profitable?

Do insiders & institutionals have more ownership in TEVA or ARGX?

Does the media favor TEVA or ARGX?

Which has higher earnings & valuation, TEVA or ARGX?

Do analysts rate TEVA or ARGX?

Which has more risk & volatility, TEVA or ARGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools